{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:39:51Z","timestamp":1792521591667,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Difficult-to-diagnose melanocytic neoplasms often require additional diagnostic tools beyond histopathological assessment to reach a definitive diagnosis. The 23-gene expression profile (GEP) test provides additional diagnostic information, returning a result of\n                    <jats:italic toggle=\"yes\">suggestive of benign<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">intermediate<\/jats:italic>\n                    , or\n                    <jats:italic toggle=\"yes\">suggestive of malignant<\/jats:italic>\n                    . Here, we present a real-world cohort of ambiguous melanocytic lesions where the 23-GEP test was used to arrive at a definitive diagnosis with long-term follow-up. Melanocytic lesions were included in this study if 23-GEP testing was performed as part of their original diagnostic workup (n = 267). Long-term follow-up to determine disease recurrence and\/or metastasis (ie, an event) was obtained (median, 6 years). Following 23-GEP testing, 89.5% of difficult-to-diagnose lesions were provided definitive diagnoses. Event rates were 11.5% for lesions with malignant 23-GEP results, 2.9% for lesions with intermediate results, and 1.3% for lesions with benign results (Fisher exact,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.002). Lesions with at least 5 years of clinical follow-up and\/or an event (n = 163) had similar results to the overall cohort (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.007). A benign 23-GEP result is associated with a low risk of recurrence\/metastasis, whereas a malignant 23-GEP result is associated with a significantly higher risk of recurrence\/metastasis, supporting the value of 23-GEP in guiding clinical management decisions for ambiguous melanocytic lesions.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000003419","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:00:55Z","timestamp":1788897655000},"page":"878-882","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes Support Utilization of 23-GEP in Clinically Ambiguous Melanocytic Neoplasms"],"prefix":"10.1097","volume":"48","author":[{"given":"Kavenpreet S.","family":"Bal","sequence":"first","affiliation":[{"name":"Kaiser Permanente, Bernard J. Tyson School of Medicine, Pasadena, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Bernard J. Tyson School of Medicine, Pasadena, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Doan","sequence":"additional","affiliation":[{"name":"Loma Linda University Health, Dermatology Residency, Loma Linda, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Liang","sequence":"additional","affiliation":[{"name":"University of Washington, Anatomic and Clinical Pathology Residency, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8875-0858","authenticated-orcid":false,"given":"David S.","family":"Cassarino","sequence":"additional","affiliation":[{"name":"Los Angeles Medical Center, Department of Pathology, Kaiser Permanente, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"R1-20261020","article-title":"National Comprehensive Cancer Network"},{"key":"R2-20261020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jmoldx.2016.05.007","article-title":"The spectrum of clinical utilities in molecular pathology testing procedures for inherited conditions and cancer: a report of the association for molecular pathology","volume":"18","author":"Joseph","year":"2016","journal-title":"J Mol Diagn."},{"key":"R3-20261020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/00313020412331283905","article-title":"The approach to the patient with a difficult melanocytic lesion","volume":"36","author":"Elder","year":"2004","journal-title":"Pathology"},{"key":"R4-20261020","doi-asserted-by":"crossref","first-page":"j2813","DOI":"10.1136\/bmj.j2813","article-title":"Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study","volume":"357","author":"Elmore","year":"2017","journal-title":"BMJ"},{"key":"R5-20261020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/cup.14635","article-title":"Diagnostic discordance among histopathological reviewers of melanocytic lesions","volume":"51","author":"Hosler","year":"2024","journal-title":"J Cutan Pathol."},{"key":"R6-20261020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/DSS.0000000000001367","article-title":"Atypical melanocytic proliferations: a review of the literature","volume":"44","author":"Ensslin","year":"2018","journal-title":"Dermatol Surg."},{"key":"R7-20261020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2023.05.002","article-title":"Ancillary testing for melanoma: current trends and practical considerations","volume":"140","author":"Hosler","year":"2023","journal-title":"Hum Pathol."},{"key":"R8-20261020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cup.14135","article-title":"Appropriate use criteria for ancillary diagnostic testing in dermatopathology: new recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee","volume":"49","author":"Fung","year":"2022","journal-title":"J Cutan Pathol."},{"key":"R9-20261020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"R11-20261020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cup.12475","article-title":"Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma","volume":"42","author":"Clarke","year":"2015","journal-title":"J Cutan Pathol."},{"key":"R12-20261020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/bmm.15.11","article-title":"Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions","volume":"9","author":"Warf","year":"2015","journal-title":"Biomarkers Med."},{"key":"R13-20261020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/DAD.0000000000002808","article-title":"Appropriate statistical methods to assess cross-study diagnostic 23-gene expression profile test performance for cutaneous melanocytic neoplasms","volume":"46","author":"Goldberg","year":"2024","journal-title":"Am J Dermatopathol."},{"key":"R14-20261020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cncr.30385","article-title":"An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi","volume":"123","author":"Clarke","year":"2017","journal-title":"Cancer"},{"key":"R15-20261020","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1055-9965.EPI-16-0958","article-title":"Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes","volume":"26","author":"Ko","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"R16-20261020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.humpath.2018.12.001","article-title":"Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions","volume":"86","author":"Ko","year":"2019","journal-title":"Hum Pathol."},{"key":"R17-20261020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pme-2020-0048","article-title":"Clinical validity of a gene expression signature in diagnostically uncertain neoplasms","volume":"17","author":"Clarke","year":"2020","journal-title":"Per Med."},{"key":"R18-20261020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.humpath.2023.07.002","article-title":"Real world validation of an adjunctive gene expression profiling assay for melanoma diagnosis and correlation with clinical outcomes at an academic center","volume":"139","author":"Boothby-Shoemaker","year":"2023","journal-title":"Hum Pathol."},{"key":"R19-20261020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmjebm-2023-112460","article-title":"Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method","volume":"29","author":"Adamson","year":"2024","journal-title":"BMJ Evid Based Med."},{"key":"R20-20261020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jamadermatol.2022.0097","article-title":"To improve melanoma outcomes, focus on risk stratification, not overdiagnosis","volume":"158","author":"Kulkarni","year":"2022","journal-title":"JAMA Dermatol."},{"key":"R21-20261020","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.5858\/arpa.2015-0207-RA","article-title":"Atypical spitz tumors: a diagnostic challenge","volume":"139","author":"Harms","year":"2015","journal-title":"Arch Pathol Lab Med."},{"key":"R22-20261020","doi-asserted-by":"crossref","first-page":"e4887","DOI":"10.1097\/MD.0000000000004887","article-title":"The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists","volume":"95","author":"Cockerell","year":"2016","journal-title":"Medicine"},{"key":"R23-20261020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/pme-2016-0097","article-title":"The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions","volume":"14","author":"Cockerell","year":"2017","journal-title":"Per Med."},{"key":"R24-20261020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.12788\/cutis.0254","article-title":"Clinical use of a diagnostic gene expression signature for melanocytic neoplasms","volume":"107","author":"Tschen","year":"2021","journal-title":"Cutis"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:00:15Z","timestamp":1792519215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003419","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}